Literature DB >> 11932749

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.

Ina Rhee1, Kurtis E Bachman, Ben Ho Park, Kam-Wing Jair, Ray-Whay Chiu Yen, Kornel E Schuebel, Hengmi Cui, Andrew P Feinberg, Christoph Lengauer, Kenneth W Kinzler, Stephen B Baylin, Bert Vogelstein.   

Abstract

Inactivation of tumour suppressor genes is central to the development of all common forms of human cancer. This inactivation often results from epigenetic silencing associated with hypermethylation rather than intragenic mutations. In human cells, the mechanisms underlying locus-specific or global methylation patterns remain unclear. The prototypic DNA methyltransferase, Dnmt1, accounts for most methylation in mouse cells, but human cancer cells lacking DNMT1 retain significant genomic methylation and associated gene silencing. We disrupted the human DNMT3b gene in a colorectal cancer cell line. This deletion reduced global DNA methylation by less than 3%. Surprisingly, however, genetic disruption of both DNMT1 and DNMT3b nearly eliminated methyltransferase activity, and reduced genomic DNA methylation by greater than 95%. These marked changes resulted in demethylation of repeated sequences, loss of insulin-like growth factor II (IGF2) imprinting, abrogation of silencing of the tumour suppressor gene p16INK4a, and growth suppression. Here we demonstrate that two enzymes cooperatively maintain DNA methylation and gene silencing in human cancer cells, and provide compelling evidence that such methylation is essential for optimal neoplastic proliferation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932749     DOI: 10.1038/416552a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  456 in total

1.  DNA methylation density influences the stability of an epigenetic imprint and Dnmt3a/b-independent de novo methylation.

Authors:  Matthew C Lorincz; Dirk Schübeler; Shauna R Hutchinson; David R Dickerson; Mark Groudine
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.

Authors:  F Neri; D Dettori; D Incarnato; A Krepelova; S Rapelli; M Maldotti; C Parlato; P Paliogiannis; S Oliviero
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

3.  Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc.

Authors:  Cuk-Seong Kim; Young-Rae Kim; Asma Naqvi; Santosh Kumar; Timothy A Hoffman; Saet-Byel Jung; Ajay Kumar; Byeong-Hwa Jeon; Dennis M McNamara; Kaikobad Irani
Journal:  Cardiovasc Res       Date:  2011-09-20       Impact factor: 10.787

4.  Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.

Authors:  David J Hughes; Elessa M Marendy; Carol A Dickerson; Kristen D Yetming; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 5.  DNA methylation and microRNAs in cancer.

Authors:  Xiang-Quan Li; Yuan-Yuan Guo; Wei De
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

6.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

7.  Suppression of intestinal neoplasia by deletion of Dnmt3b.

Authors:  Haijiang Lin; Yasuhiro Yamada; Suzanne Nguyen; Heinz Linhart; Laurie Jackson-Grusby; Alexander Meissner; Konstantinos Meletis; Grace Lo; Rudolf Jaenisch
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

8.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.

Authors:  Yeonjoo Jung; Jinah Park; Tai Young Kim; Jung-Hyun Park; Hyun-Soon Jong; Seock-Ah Im; Keith D Robertson; Yung-Jue Bang; Tae-You Kim
Journal:  J Mol Med (Berl)       Date:  2007-06-15       Impact factor: 4.599

10.  DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells.

Authors:  Jon M McGough; Dafeng Yang; Shuang Huang; David Georgi; Stephen M Hewitt; Christoph Röcken; Marc Tänzer; Matthias P A Ebert; Kebin Liu
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.